Cargando…

Occurrence of abscesses during treatment with pazopanib in metastatic renal cancer: a case report

BACKGROUND: Pazopanib is a multitarget tyrosine kinase inhibitor used in the treatment of renal cancer and soft tissue sarcoma. Its use is commonly associated with a number of side effects, such as hemorrhagic diathesis, neutropenia, leukopenia, thrombocytopenia, nausea, vomiting, abdominal pain, in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puliafito, Ivana, Russo, Alessio, Sciacca, Dorotea, Puglisi, Caterina, Giuffrida, Dario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954518/ https://www.ncbi.nlm.nih.gov/pubmed/31924259 http://dx.doi.org/10.1186/s13256-019-2318-y

Ejemplares similares

Target Therapy in Thyroid Cancer: Current Challenge in Clinical Use of Tyrosine Kinase Inhibitors and Management of Side Effects
por: Puliafito, Ivana, et al.
Publicado: (2022)

Metabolic complete tumor response in a patient with epidermal growth factor receptor mutant non-small cell lung cancer treated with a reduced dose of afatinib
por: Puliafito, Ivana, et al.
Publicado: (2022)

Thyroidectomy as Treatment of Choice for Differentiated Thyroid Cancer
por: Giuffrida, Dario, et al.
Publicado: (2019)

Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma
por: Rossetti, Sabrina, et al.
Publicado: (2017)

Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis
por: Puliafito, Ivana, et al.
Publicado: (2023)

Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
por: Iyer, Ridhima, et al.
Publicado: (2017)

Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma
por: Bukowski, Ronald M
Publicado: (2011)

Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib
por: Kawahara, Takashi, et al.
Publicado: (2019)

One year survivor of metastatic renal cell carcinoma treated with pazopanib
por: Inn, Fam Xeng, et al.
Publicado: (2017)

Delayed nivolumab‐induced hepatotoxicity during pazopanib treatment for metastatic renal cell carcinoma: An autopsy case
por: Todo, Maki, et al.
Publicado: (2019)

Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report
por: Jeon, So-Yeon, et al.
Publicado: (2019)

Role of the Combination of Cyclin-Dependent Kinase Inhibitors (CDKI) and Radiotherapy (RT) in the Treatment of Metastatic Breast Cancer (MBC): Advantages and Risks in Clinical Practice
por: Gagliano, Ambrogio, et al.
Publicado: (2021)

Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib
por: Fiala, Ondřej, et al.
Publicado: (2021)

Successful use of pazopanib for treatment of refractory metastatic hemangiopericytoma
por: Lee, Su Jin, et al.
Publicado: (2014)

The Successful Treatment of Metastatic Extraosseous Ewing Sarcoma with Pazopanib
por: Mori, Yoshinori, et al.
Publicado: (2018)

Pazopanib-Induced Liver Injury in Patients With Metastatic Renal Cell Carcinoma: A Report of Two Cases
por: Ouchi, Ryusuke, et al.
Publicado: (2022)

A Case of Cardiac Tamponade in a Patient with Metastatic Renal Cell Carcinoma on Pazopanib Treatment
por: Sarathy, Vinu, et al.
Publicado: (2020)

Clinical Outcome of Third-Line Pazopanib in a Patient with Metastatic Renal Cell Carcinoma
por: Roberto, Michela, et al.
Publicado: (2015)

Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom
por: Amdahl, Jordan, et al.
Publicado: (2017)

Pazopanib as salvage therapy in metastatic renal cell carcinoma with hypercalcemic crisis and renal insufficiency: a case report and literature review
por: Chen, Ying, et al.
Publicado: (2020)

Pazopanib for the Treatment of Patients with Advanced Renal Cell Carcinoma
por: Lang, Joshua M., et al.
Publicado: (2010)

Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
por: Grassi, Paolo, et al.
Publicado: (2017)

Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma
por: Attia, Steven, et al.
Publicado: (2015)

Pazopanib in rare histologies of metastatic soft tissue sarcoma
por: Kataria, Babita, et al.
Publicado: (2021)

Oral Side Effects in Patients with Metastatic Renal Cell Carcinoma Receiving the Antiangiogenic Agent Pazopanib—Report of Three Cases
por: Papadopoulou, Erofili, et al.
Publicado: (2022)

Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib
por: Koutsoukos, Konstantinos, et al.
Publicado: (2017)

Durable Response to Pazopanib in Recurrent Metastatic Carotid Body Paraganglioma
por: Alshamsan, Bader, et al.
Publicado: (2020)

Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network
por: Shantakumar, Sumitra, et al.
Publicado: (2016)

Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review
por: Bersanelli, Melissa, et al.
Publicado: (2020)

Pazopanib together with 6–8 cycles of sintilimab followed by single use of pazopanib in the second-line treatment of advanced renal cell carcinoma
por: Lu, Xiaolin, et al.
Publicado: (2021)

Efficacy of Pazopanib in the Treatment of Metastatic Malignant Giant Cell Tumor of Soft Tissue: A Case Report
por: Iwai, Tadashi, et al.
Publicado: (2022)

Pazopanib in Metastatic Renal Cancer: A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale”
por: Cecere, Sabrina C., et al.
Publicado: (2016)

Pazopanib in patients with metastatic renal cell carcinoma: a single-center, real-world, retrospective Chinese study
por: Chen, Jianhui, et al.
Publicado: (2021)

New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib
por: Cowey, C Lance, et al.
Publicado: (2010)

Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours
por: Ahn, H K, et al.
Publicado: (2013)

Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma
por: Fruehauf, John P., et al.
Publicado: (2018)

First-Line Pazopanib Treatment in Metastatic Renal Cell Carcinoma: Real-World Data From a Single Chinese Center
por: Wang, Bin, et al.
Publicado: (2020)

Clinical Benefit of Pazopanib in a Patient with Metastatic Chondrosarcoma: A Case Report and Review of the Literature
por: Tsavaris, Onoufrios, et al.
Publicado: (2018)

Pazopanib as a second-line treatment for non-cytokine-treated metastatic renal cell carcinoma: a meta-analysis of the effect of treatment
por: Kok, Victor C., et al.
Publicado: (2016)

Identification of biomarkers in pazopanib treated patients with renal cell carcinoma
por: Pick, Amy M., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_t75b90id61d7gk59vfck2p60e5